Price Alert: Shares of Akari (AKTX) Trade 11.67% Higher at Midday August 5

Equities Staff  |

Today Akari Therapeutics Plc - ADR (NASDAQ: AKTX) is trading 11.67% up.

The latest price, as of 11:45:37 est, was $1.41. Akari has climbed $0.147 in trading today.

47,039 shares have traded hands.

As of the previous close, Akari has moved YTD 6.00%. The company anticipates its next earnings on 2022-09-01.

For technical charts, analysis, and more on Akari visit the company profile.

About Akari Therapeutics Plc - ADR

Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically for the treatment of rare and orphan diseases, in particular those where the complement (C5) or leukotriene (LTB4) systems, or both complement and leukotrienes together, play a primary role in disease progression. Akari's lead drug candidate, nomacopan (formerly known as Coversin), is a C5 complement inhibitor that also independently and specifically inhibits leukotriene B4 (LTB4) activity.

To get more information on Akari Therapeutics Plc - ADR and to follow the company's latest updates, you can visit the company's profile page here: Akari Therapeutics Plc - ADR's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation



Market Movers

Sponsored Financial Content